Literature DB >> 26493796

Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.

Lara J Wolfson1, Judith Gibbert2, Daniel Wirth3, Roland Diel4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26493796     DOI: 10.1183/13993003.00811-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  2 in total

1.  Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.

Authors:  Daniel Wirth; Ramesh Dass; Robert Hettle
Journal:  BMC Health Serv Res       Date:  2017-03-08       Impact factor: 2.655

2.  Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.

Authors:  Gabriela Beatriz Gomez; Mariana Siapka; Francesca Conradie; Norbert Ndjeka; Anna Marie Celina Garfin; Nino Lomtadze; Zaza Avaliani; Nana Kiria; Shelly Malhotra; Sarah Cook-Scalise; Sandeep Juneja; Daniel Everitt; Melvin Spigelman; Anna Vassall
Journal:  BMJ Open       Date:  2021-12-03       Impact factor: 3.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.